NASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis → REPLAY AVAILABLE: $0.25 Cent Trades (From DTI) (Ad) Free BLUE Stock Alerts $0.94 -0.03 (-3.09%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$0.92▼$1.0050-Day Range$0.89▼$1.4652-Week Range$0.85▼$5.53Volume4.78 million shsAverage Volume6.37 million shsMarket Capitalization$102.79 millionP/E RatioN/ADividend YieldN/APrice Target$5.74 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get bluebird bio alerts: Email Address bluebird bio MarketRank™ Stock AnalysisAnalyst RatingHold2.27 Rating ScoreUpside/Downside511.0% Upside$5.74 Price TargetShort InterestBearish28.90% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.72) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.98 out of 5 starsMedical Sector594th out of 931 stocksBiological Products, Except Diagnostic Industry94th out of 153 stocks 3.1 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst Coveragebluebird bio has only been the subject of 4 research reports in the past 90 days.Read more about bluebird bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted28.90% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in bluebird bio has recently decreased by 0.82%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 2.5 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for bluebird bio this week, compared to 6 articles on an average week.Search InterestOnly 23 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat Follows12 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about bluebird bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($1.72) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis indicator is great for calling bottoms“It was designed to help boost your chances of finding rock solid trade ideas” It’s called the “Master Indicator” And it’s quite possibly one of the most useful indicators you’ll ever use.If you’d like to join me just follow this link here. About bluebird bio Stock (NASDAQ:BLUE)bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More BLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Stock News HeadlinesMay 29 at 7:00 AM | businesswire.combluebird bio Appoints O. James Sterling as Chief Financial OfficerMay 27 at 12:46 PM | stockhouse.comDEADLINE TOMORROW: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmMay 25, 2024 | theglobeandmail.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUEMay 25, 2024 | finance.yahoo.comBLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?May 24, 2024 | tmcnet.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)May 24, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)May 23, 2024 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUEMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUEMay 22, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitMay 21, 2024 | prnewswire.comInvestors in bluebird bio, Inc. Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUEMay 17, 2024 | businesswire.comBLUE INVESTOR ALERT: Kirby McInerney LLP Notifies bluebird bio, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitMay 16, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitMay 16, 2024 | fool.comIs Bluebird Bio Stock a Buy?May 15, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmMay 15, 2024 | prnewswire.comLevi & Korsinsky Notifies Shareholders of bluebird bio, Inc.(BLUE) of a Class Action Lawsuit and an Upcoming DeadlineMay 14, 2024 | prnewswire.comROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action - BLUEMay 14, 2024 | prnewswire.comClass Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law FirmMay 13, 2024 | businesswire.comBLUE INVESTOR ALERT: Kirby McInerney LLP Notifies bluebird bio, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitMay 13, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitMay 13, 2024 | prnewswire.comShareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMay 11, 2024 | seekingalpha.combluebird bio, Inc. (BLUE) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.combluebird bio, Inc. (NASDAQ:BLUE) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.combluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...May 9, 2024 | msn.combluebird bio reports Q1 resultsMay 9, 2024 | finance.yahoo.combluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 GuidanceSee More Headlines Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today5/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$5.74 High Stock Price Target$13.00 Low Stock Price Target$1.02 Potential Upside/Downside+511.0%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-266,580,000.00 Net Margins-419.64% Pretax Margin-419.50% Return on Equity-34.32% Return on Assets-14.44% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.42 Sales & Book Value Annual Sales$3.60 million Price / Sales28.55 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.40Miscellaneous Outstanding Shares109,340,000Free Float107,040,000Market Cap$102.79 million OptionableOptionable Beta0.82 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Andrew Obenshain (Age 50)President, CEO & Director Comp: $1.04MMr. Thomas J. Klima (Age 52)Chief Commercial Officer & COO Comp: $654.97kMr. Richard A. Colvin M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $696.24kMr. Christopher Krawtschuk CPA (Age 50)CFO, Principal Accounting Officer & Treasurer Mr. Joseph D. Vittiglio Esq. (Age 52)J.D., Chief Legal & Business Officer and Secretary Jess RowlandsHead of Corporate CommunicationsMs. Andrea WaltonChief People OfficerMr. Kasra KasraianSenior Vice President of Technical Development & OperationsMr. Scott ShoemakerSenior Vice President of QualityMs. Sarah AlspachSenior Vice President of External AffairsMore ExecutivesKey CompetitorsSangamo TherapeuticsNASDAQ:SGMOAlloVirNASDAQ:ALVRFate TherapeuticsNASDAQ:FATEC4 TherapeuticsNASDAQ:CCCCJasper TherapeuticsNASDAQ:JSPRView All CompetitorsInsiders & InstitutionsBayesian Capital Management LPBought 40,443 shares on 5/16/2024Ownership: 0.037%Price T Rowe Associates Inc. MDBought 29,113 shares on 5/15/2024Ownership: 0.050%American International Group Inc.Bought 41,177 shares on 5/14/2024Ownership: 0.086%Vanguard Group Inc.Bought 1,723,081 shares on 5/10/2024Ownership: 9.602%SG Americas Securities LLCBought 65,710 shares on 5/7/2024Ownership: 0.073%View All Insider TransactionsView All Institutional Transactions BLUE Stock Analysis - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price target for 2024? 11 Wall Street research analysts have issued twelve-month target prices for bluebird bio's shares. Their BLUE share price targets range from $1.02 to $13.00. On average, they expect the company's share price to reach $5.74 in the next twelve months. This suggests a possible upside of 511.0% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2024? bluebird bio's stock was trading at $1.38 at the beginning of the year. Since then, BLUE shares have decreased by 31.9% and is now trading at $0.9401. View the best growth stocks for 2024 here. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) released its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to the consensus estimate of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. The firm's quarterly revenue was up 17364.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.92) EPS. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) and Global X Genomics & Biotechnology ETF (GNOM).Horizon Kinetics Medical ETF (MEDX). What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). Who are bluebird bio's major shareholders? bluebird bio's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.60%), Mirae Asset Global Investments Co. Ltd. (0.30%), BNP Paribas Financial Markets (0.09%), American International Group Inc. (0.09%), SG Americas Securities LLC (0.07%) and Price T Rowe Associates Inc. MD (0.05%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLUE) was last updated on 5/29/2024 by MarketBeat.com Staff From Our Partners4 Cryptos BETTER than BitcoinTrue Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.